AzTrials
AzTrials

Osteoarthritis of the KneePhase 2OAKNCT02611466

A Study to Assess the Analgesic Efficacy of ASP7962 in Patients With Pain Due to Osteoarthritis of the Knee

A Phase 2 study testing ASP7962 and Naproxen in people with Osteoarthritis of the Knee and Chronic Lower Back Pain, run by Astellas Pharma Europe B.V. at 34 sites in 6 countries.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

The purpose of the study is to evaluate the analgesic efficacy of ASP7962 relative to placebo. This study will also evaluate the efficacy of ASP7962 relative to placebo on pain on walking, function and stiffness; the time course of efficacy of ASP7962 relative to placebo; the improvement in overall patient status of… Read more about this study

Who is it for?
Ages 18 to 80 years
What is being tested?
ASP7962 and Naproxen
Type of treatment
Pill or oral medicine
Could I receive a placebo?
Yes, some participants may receive a placebo
How many people
215 participants
Where
34 sitesin 6 countries
Study dates
16 Feb 2016to 29 Sep 2017
Phase
Phase 2
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 80 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Patient has a primary diagnosis of OA of the index knee with symptoms for at least 6 months prior to screening and patient meets American College of Rheumatology clinical classification criteria for OA of the knee, defined by the following:
  • Knee pain and at least 3 of the following 6:
  • Age > 50 years
  • Morning stiffness < 30 minutes
  • Crepitus on active motion
  • Bony tenderness
Show all 23Show fewer
  • Bony enlargement
  • No palpable warmth of synovium
  • Patient has a radiographic image of the index knee (according to the minimum quality criteria for radiographic image as set by the central radiology reader) showing evidence of OA with a Kellgren-Lawrence grade ≥2 at screening (based on central reading).
  • Patient has moderate to severe index knee pain (pain due to OA of the knee at least 5 days per week for the last 3 months prior to screening, as determined by patient's medical history).
  • Patient is ambulatory and the index knee must not contain any orthopedic and/or prosthetic device.
  • WOMAC pain subscale score (with a 48-hour recall period) in the index knee ≥ 4 at baseline (visit 2 predose, mean of all questions on pain subscale).
  • WOMAC physical function subscale score ≥ 4 at baseline (visit 2 predose, mean of all questions on physical function subscale with a 48-hour recall period).
  • Patient is willing to discontinue all current pain medications during the baseline and treatment periods (until day 57) (except for allowed rescue medications). Low dose aspirin for cardioprophylaxis is allowed.
  • Patient is compliant with daily pain recording. Compliance with diary completion will be defined as daily average pain ratings on at least 5 days of the baseline period, of which at least 3 days are in the last 4 days prior to visit 2.
  • Male patient and their female spouse/partners who are of childbearing potential must be using a barrier method and 1 form of highly effective birth control starting at screening and continuing throughout the study period and for 90 days after the final study drug administration.
  • Male patient must not donate sperm starting at screening and throughout the study period and for 90 days after the final study drug administration.
  • Female patient must either:
  • Be of non-childbearing potential: post-menopausal (defined as at least 1 year without any menses) prior to screening, or documented surgically sterile
  • Or, if of childbearing potential: agree not to try to become pregnant during the study and for 28 days after the final study drug administration, and have a negative pregnancy test at screening and at baseline (visit 2 predose), and if heterosexually active, agree to consistently use a barrier method and 1 form of highly effective birth control starting at screening and continuing throughout the study period and for 28 days after the final study drug administration.
  • Female patient must agree not to breastfeed starting at screening and continuing throughout the study period and for 28 days after the final study drug administration.
  • Female patient must not donate ova starting at screening and continuing throughout the study period and for 28 days after the final study drug administration.
  • Patient agrees not to participate in another investigational study from screening through the follow-up period (until day 57).

Who cannot join

  • Medical History / Clinical Status:
  • Patient has a history of suicide attempt or suicidal behavior. Suicidal ideation within the last 12 months (a response of "yes" to questions 4 or 5 on the suicidal ideation portion of the Columbia-Suicide Severity Rating Scale [C-SSRS]), or who are at significant risk to commit suicide, as judged by the investigator at screening and at the time of randomization.
  • Patient has current or prior psychosis, major depressive disorder or other clinically significant psychiatric disorder.
  • Patient has a current or prior clinically significant neurologic disease, including but not limited to peripheral neuropathy, stroke, cognitive impairment and seizure. Childhood febrile seizures are not exclusionary.
  • Patient has any clinically significant uncontrolled musculoskeletal disorder (with the exception of OA), cardiovascular, gastrointestinal, endocrinologic (diabetes mellitus is allowed if controlled [glycated hemoglobin (HbA1c) ≤ 8.0%] and no peripheral neuropathy), hematologic, hepatic, immunologic, metabolic, urologic, pulmonary, dermatologic, renal and/or other major disease.
  • Patient has an active malignancy or a history of malignancy (except for treated nonmelanoma skin cancer) within the past 5 years.
Show all 56Show fewer
  • Patient has a history of inflammatory arthritis, (including rheumatoid arthritis or a history of RPOA, osteonecrosis or avascular necrosis of bone and/or joints), or has other diagnoses that may increase the risk of RPOA (e.g., pre-existing atrophic OA, subchondral insufficiency fracture), or severe knee malalignment or any other joint-related condition that makes the patient unsuitable for study participation (e.g., joint pain that is disproportionately severe, or which has atypical features for OA pain, should trigger further medical evaluation to rule out subchondral insufficiency fracture).
  • Patient has findings suggestive of RPOA or increased risk for RPOA on screening radiographs of either index or non-index joints (based on central reading).
  • Patient has a history of shoulder surgery, clinically significant trauma or current symptoms, including pain or impaired range of motion at shoulder joint.
  • Patient has a coagulopathy, is receiving anticoagulants or has been diagnosed with thrombocytopenia or a functional platelet disorder.
  • Patient has a history of paracetamol intolerance, or existence of medical condition or use of concomitant medication for which paracetamol is contraindicated.
  • Patient has any contraindication to naproxen including but not limited to:
  • Known hypersensitivity to tramadol (a patient with intolerance or hypersensitivity is allowed, if the patient accepts to limit rescue medication toparacetamol).
  • Asthma, rhinitis, nasal polyps, urticarial or allergic-type reactions after taking aspirin or other nonsteroidal anti-inflammatory drugs (NSAIDs).
  • Anticipated coronary artery bypass graft surgery during the study.
  • Active or history of peptic ulceration.
  • Active or history of gastrointestinal bleeding (with the exception of hemorrhoids) or perforation.
  • Patient has any contraindication to tramadol including but not limited to
  • Known hypersensitivity to tramadol.
  • Patient has used a monoamine oxidase inhibitor within 2 weeks prior to screening or during the screening or baseline periods.
  • Patient has a body mass index (BMI) > 39 kg/m2.
  • Cardiovascular:
  • Patient has a clinically significant abnormality on 12-lead electrocardiogram (ECG) at screening or baseline (visit 2 predose).
  • Patient has any of the following:
  • Lifetime history of ischemic or hemorrhagic stroke, cardiac arrest, torsade de pointes, clinically significant structural heart disease or a personal or family history of long QT syndrome.
  • Within 12 months prior to visit 2: acute coronary syndrome (e.g., myocardial infarction, unstable angina [ischemic heart disease is allowed]); transient ischemic attack; coronary or peripheral revascularization procedure; clinically significant cardiac arrhythmias (including atrial fibrillation or flutter), heart block (first degree heart block is allowed provided PR interval is not greater than 240 msec) or other clinically significant cardiovascular disorder.
  • Current heart failure (New York Heart Association [NYHA] class III and IV).
  • Patient has a resting pulse rate < 50 or > 100 beats per minute (bpm); systolic blood pressure (SBP) > 160 mm Hg; diastolic blood pressure (DBP) > 90 mm Hg at screening or baseline (visit 2 predose). These assessments may be repeated once, after a reasonable time period at the investigator's discretion. If the repeat measurement is meeting the above criteria, the patient will be excluded.
  • Patient has a history of unexplained syncopal events or has symptomatic orthostatic hypotension at screening or baseline (visit 2 predose), defined as postural related symptoms and at least one of the following: standing SBP ≥ 20 mm Hg lower than supine SBP, standing DBP ≥ 10 mm Hg lower than supine DBP.
  • Clinical Chemistry / Hematology:
  • Patient has (according to the investigator) clinically significant abnormalities in clinical chemistry, hematology or urinalysis at screening. These assessments may be repeated once, after a reasonable time period at the investigator's discretion (but within the screening period).
  • Patient has any liver tests (aspartate aminotransferase [AST], alanine aminotransferase [ALT], total bilirubin [TBL]) > 1.5 times the upper limit of normal [ULN] at screening. These assessments may be repeated once, after a reasonable time period at the investigator's discretion (but within the screening period).
  • Patient has an estimated glomerular filtration rate of ≤ 60 mL/min/1.73m2 (Modification of Diet in Renal Disease [MDRD] calculation) at screening.
  • Patient has a positive test result for hepatitis B surface antigen (HBsAg), hepatitis A virus antibodies (immunoglobulin M) (anti-HAV [IgM]), hepatitis C virus antibodies (anti-HCV), or antibodies to human immunodeficiency virus type 1(HIV-1) and/or type 2 (HIV-2) at screening.
  • Prior Medication / Medical Intervention:
  • Patient has received any investigational drug within 28 days (or 5 half-lives of the investigational drug, whichever is longer) before screening or is scheduled to receive an investigational drug other than blinded study treatments during the course of this study.
  • Patient has previously received antibodies to NGF within 3 months prior to screening.
  • Patient has had any major surgery or orthopedic surgery within 3 months before screening or has plans for surgical intervention during the study.
  • Patient who is not a suitable candidate for joint replacement surgery and who is unable to stop chronic NSAID use.
  • Patient has received intra-articular corticosteroid or intra-articular local anesthetics within 3 months prior to screening, intra-articular hyaluronic acid within 6 months prior to screening or any of these therapies during the screening or baseline periods.
  • Patient has received systemic corticosteroids within the past 30 days before screening or during the screening or baseline periods (topical, nasal and inhaled corticosteroids are permitted.)
  • Patient has received any medications or nonmedication therapy with efficacy in reducing pain of OA of the knee, including over-the-counter (OTC) products (with the exception of ice packs, rest, and paracetamol) during the baseline period.
  • Patient has started or stopped physiotherapy, acupuncture or transcutaneous electrical nerve stimulation related to treatment of the index knee within 4 weeks prior to screening or during the screening or baseline periods. Stable regimens of these therapies introduced more than 4 weeks prior to screening will be allowed if the regimen is to continue unchanged during the study.
  • Patient has used opioids for more than 4 days during the week preceding screening or during the screening period; or has received any opioids during the baseline period.
  • Patient has used dipeptidyl peptidase 4 (DPP-4) inhibitors within 12 months prior to visit 2.
  • Patient has regularly used any strong systemic inducer of cytochrome P450 (CYP) 3A metabolism (e.g., rifampin, St John's wort) in the 3 months before visit 2.
  • Patient has not complied with the requirements for restricted and prohibited medications and nonmedication therapies during the baseline period.
  • Recreational Drug Use:
  • Patient has a positive drug screen for alcohol or recreational drugs (including cannabinoids) or nonprescribed controlled substances at screening (these assessments may be repeated once, after a reasonable time period at the investigator's discretion, but within the screening period) or at baseline.
  • Patient has a history of alcohol or drug abuse/dependence/misuse within 1 year prior to screening.
  • General:
  • Patient has any painful condition syndrome (e.g., neuropathy, fibromyalgia) or other concurrent medical or arthritic condition that has the potential to confound the assessment of pain in the index knee, in the investigator's opinion.
  • Patient has a Hospital Anxiety and Depression Scale (HADS) score > 12 on either subscale at screening or baseline (visit 2 predose).
  • Patient is involved in an ongoing or settled workers compensation claim, disability or litigation related to the index knee or any pain problem.
  • Any condition that, in the investigator's opinion, makes the patient unsuitable for study participation.
  • Patient is an employee of the Astellas Group, the Contract Research Organization (CRO) involved or the investigator site executing the study.

Trial locations and contacts

34 sites in 6 countries.

34 sites in 6 countries

Hungary9 sites

  • Site HU36002

    Baja, 6500

  • Site HU36008

    Balatonfüred, 8230

  • Site HU36005

    Békéscsaba, 5600

  • Site HU36007

    Budapest, 1027

  • Site HU36006

    Debrecen, 4032

  • Site HU36001

    Esztergom, 2500

  • Site HU36003

    Komárom, 2900

  • Site HU36009

    Szeged, 6722

  • Site HU36004

    Veszprém, 8200

Other trials in Hungary

Spain8 sites

  • Site ES34002

    A Coruña, 15006

  • Site ES34001

    Barakaldo, 48903

  • Site ES34008

    Barcelona, 8028

  • Site ES34012

    Barcelona, 8034

  • Site ES34003

    Bilbao, 48013

  • Site ES34005

    Madrid, 28046

  • Site ES34004

    Santiago de Compostela, 15702

  • Site ES34010

    Valencia, 46015

Other trials in Spain

Germany6 sites

  • Site DE49007

    Bayern, 80639

  • Site DE49006

    Berlin, 10629

  • Site DE49004

    Deggingen, 73326

  • Site DE49003

    Leipzig, 4108

  • Site DE49001

    Magdeburg, 39120

  • Site DE49005

    Munich, 80809

Other trials in Germany

Czechia4 sites

  • Site CZ42006

    Hradec Králové, 50341

  • Site CZ42003

    Kunovice, 686 04

  • Site CZ42002

    Prague, 14000

  • Site CZ42005

    Prague, 14059

Other trials in Czechia

United Kingdom4 sites

  • Site GB44006

    London, NW3 2QG

  • Site GB44011

    North Shields, NE29 8NH

  • Site GB44010

    Oxfordshire, OX3 7LD

  • Site GB44012

    West Midlands, WS11 5XY

Other trials in United Kingdom

Belgium3 sites

  • Site BE32003

    Leuven, 3000

  • Site BE32002

    Merksem, 2170

  • Site BE32004

    Yvoir, 5530

Other trials in Belgium

About this study

Official title: A Phase 2a, Randomized, Double-blind, Placebo- and Naproxen Controlled, Parallel-group Study to Assess the Analgesic Efficacy of ASP7962 in Patients With Pain Due to Osteoarthritis of the Knee

The purpose of the study is to evaluate the analgesic efficacy of ASP7962 relative to placebo.

This study will also evaluate the efficacy of ASP7962 relative to placebo on pain on walking, function and stiffness; the time course of efficacy of ASP7962 relative to placebo; the improvement in overall patient status of ASP7962 relative to placebo as well as the safety and tolerability of ASP7962 relative to placebo.

Being tested
ASP7962, Naproxen, Placebo
Keywords
Osteoarthritis, ASP7962
Medical subject headings
Osteoarthritis, Knee, Osteoarthritis

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • ASP7962Drug

    Participants receive ASP7962 100 mg orally twice daily, in the morning and evening with or without food (approximately 12 hours).

  • NaproxenDrug

    Participants receive naproxen 500 mg orally twice daily, in the morning and evening with or without food (approximately 12 hours).

  • PlaceboDrug

    Participants receive matching placebo orally twice daily, in the morning and evening with or without food (approximately 12 hours).

Study groups in NCT02611466
Study groupRoleWhat they receive
ASP7962ExperimentalParticipants receive 100 mg of ASP7962 orally twice daily for 4 weeks.
Receives: Drug: ASP7962
NaproxenActive comparatorParticipants receive 500 mg of naproxen orally twice daily for 4 weeks.
Receives: Drug: Naproxen
PlaceboPlacebo comparatorParticipants receive placebo orally twice daily for a period of 4 weeks.
Receives: Drug: Placebo

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Change from Baseline to Week 4 in Western Ontario and McMaster Universities Arthritis Index (WOMAC) Pain Subscale Score

    WOMAC is a tri-dimensional, self-administered, patient-centered health status questionnaire designed to capture the elements of pain, stiffness and physical function in participants with OA of the knee and/or hip joints. The questionnaire consists of 24 questions, which are divided into three subscales: pain (5 questions), stiffness (2 questions) and physical function (17 questions). Each question is scored using 11-point NRS scale ranging from 0 (none) to 10 (extreme). The pain subscale contains five questions that ask about pain during the last 48 hours caused by arthritis in the index knee. A negative change indicates a reduction/improvement from baseline.

    Measured: Baseline and Week 4

Secondary outcomes (19)

  1. Change from Baseline to End of Treatment (EOT) in WOMAC Pain Subscale Score

    WOMAC is a tri-dimensional, self-administered, patient-centered health status questionnaire designed to capture the elements of pain, stiffness and physical function in participants with OA of the knee and/or hip joints. The questionnaire consists of 24 questions, which are divided into three subscales: pain (5 questions), stiffness (2 questions) and physical function (17 questions). Each question is scored using 11-point Numerical Rating Scale (NRS) scale ranging from 0 (none) to 10 (extreme). The pain subscale contains five questions that ask about pain during the last 48 hours caused by arthritis in the index knee. A negative change indicates a reduction/improvement from baseline.

    Measured: Baseline and EOT (up to 4 weeks)

  2. Change from Baseline to EOT in WOMAC Physical Function Subscale Score

    WOMAC is a tri-dimensional, self-administered, patient-centered health status questionnaire designed to capture the elements of pain, stiffness and physical function in participants with OA of the knee and/or hip joints. The questionnaire consists of 24 questions, which are divided into three subscales: pain (5 questions), stiffness (2 questions) and physical function (17 questions). Each question is scored using 11-point NRS scale ranging from 0 (none) to 10 (extreme). The physical function subscale contains 17 questions that ask about the difficulty following daily physical activities. A negative change indicates a reduction/improvement from baseline.

    Measured: Baseline and EOT (up to 4 weeks)

  3. Change from Baseline to EOT in WOMAC Stiffness Subscale Score

    WOMAC is a tri-dimensional, self-administered, patient-centered health status questionnaire designed to capture the elements of pain, stiffness and physical function in participants with OA of the knee and/or hip joints. The questionnaire consists of 24 questions, which are divided into three subscales: pain (5 questions), stiffness (2 questions) and physical function (17 questions). Each question is scored using 11-point NRS scale ranging from 0 (none) to 10 (extreme). The stiffness subscale contains two questions that ask about stiffness during the last 48 hours caused by the arthritis. A negative change indicates a reduction/improvement from baseline.

    Measured: Baseline and EOT (up to 4 weeks)

  4. Change from Baseline to EOT in WOMAC Total Score

    WOMAC is a tri-dimensional, self-administered, patient-centered health status questionnaire designed to capture the elements of pain, stiffness and physical function in participants with OA of the knee and/or hip joints. The questionnaire consists of 24 questions, which are divided into three subscales: pain (5 questions), stiffness (2 questions) and physical function (17 questions). Each question is scored using 11-point NRS scale ranging from 0 (none) to 10 (extreme). The total score is the sum of scores from pain, physical function and stiffness subscales. Total score ranges from 0 to 30. A negative change indicates a reduction/improvement from baseline.

    Measured: Baseline and EOT (up to 4 weeks)

  5. Change from Baseline to EOT in WOMAC Walking Pain Score

    WOMAC is a tri-dimensional, self-administered, patient-centered health status questionnaire designed to capture the elements of pain, stiffness and physical function in participants with OA of the knee and/or hip joints. The questionnaire consists of 24 questions, which are divided into three subscales: pain (5 questions), stiffness (2 questions) and physical function (17 questions). Each question is scored using 11-point NRS scale ranging from 0 (none) to 10 (extreme). The walking pain score is based on question 1 of the questionnaire on pain when walking on a flat surface. A negative change indicates a reduction/improvement from baseline.

    Measured: Baseline and EOT (up to 4 weeks)

  6. Change from Baseline to Weeks 1 and 2 in WOMAC Pain Subscale Score

    WOMAC is a tri-dimensional, self-administered, patient-centered health status questionnaire designed to capture the elements of pain, stiffness and physical function in participants with OA of the knee and/or hip joints. The questionnaire consists of 24 questions, which are divided into three subscales: pain (5 questions), stiffness (2 questions) and physical function (17 questions). Each question is scored using 11-point NRS scale ranging from 0 (none) to 10 (extreme). The pain subscale contains five questions that ask about pain during the last 48 hours caused by arthritis in the index knee. A negative change indicates a reduction/improvement from baseline.

    Measured: Baseline and Weeks 1 and 2

  7. Change from Baseline to Weeks 1, 2 and 4 in WOMAC Physical Function Subscale Score

    WOMAC is a tri-dimensional, self-administered, patient-centered health status questionnaire designed to capture the elements of pain, stiffness and physical function in participants with OA of the knee and/or hip joints. The questionnaire consists of 24 questions, which are divided into three subscales: pain (5 questions), stiffness (2 questions) and physical function (17 questions). Each question is scored using 11-point NRS scale ranging from 0 (none) to 10 (extreme). The physical function subscale contains 17 questions that ask about the difficulty following daily physical activities. A negative change indicates a reduction/improvement from baseline.

    Measured: Baseline and Weeks 1, 2, and 4

  8. Change from Baseline to Weeks 1, 2 and 4 in WOMAC Stiffness Subscale Score

    WOMAC is a tri-dimensional, self-administered, patient-centered health status questionnaire designed to capture the elements of pain, stiffness and physical function in participants with OA of the knee and/or hip joints. The questionnaire consists of 24 questions, which are divided into three subscales: pain (5 questions), stiffness (2 questions) and physical function (17 questions). Each question is scored using 11-point NRS scale ranging from 0 (none) to 10 (extreme). The stiffness subscale contains two questions that ask about stiffness during the last 48 hours caused by the arthritis. A negative change indicates a reduction/improvement from baseline.

    Measured: Baseline and Weeks 1, 2, and 4

  9. Change from Baseline to Weeks 1, 2 and 4 in WOMAC Total Score

    WOMAC is a tri-dimensional, self-administered, patient-centered health status questionnaire designed to capture the elements of pain, stiffness and physical function in participants with OA of the knee and/or hip joints. The questionnaire consists of 24 questions, which are divided into three subscales: pain (5 questions), stiffness (2 questions) and physical function (17 questions). Each question is scored using 11-point NRS scale ranging from 0 (none) to 10 (extreme). The total score is the sum of scores from pain, physical function and stiffness subscales. Total score ranges from 0 to 30. A negative change indicates a reduction/improvement from baseline.

    Measured: Baseline and Weeks 1, 2, and 4

  10. Change from Baseline to Weeks 1, 2 and 4 in WOMAC Walking Pain Score

    WOMAC is a tri-dimensional, self-administered, patient-centered health status questionnaire designed to capture the elements of pain, stiffness and physical function in participants with OA of the knee and/or hip joints. The questionnaire consists of 24 questions, which are divided into three subscales: pain (5 questions), stiffness (2 questions) and physical function (17 questions). Each question is scored using 11-point NRS scale ranging from 0 (none) to 10 (extreme). The walking pain score is based on question 1 of the questionnaire on pain when walking on a flat surface. A negative change indicates a reduction/improvement from baseline.

    Measured: Baseline and Weeks 1, 2, and 4

  11. Change from Baseline to Weeks 1, 2, 3, 4 and EOT in Mean Daily Average Pain Score Assessed by the Numerical Rating Scale

    The NRS is an 11-point scale used to capture the participant's average pain in the last 24 hours on a daily basis. This scale is composed of a single question and the score ranges from 0 to 10, where 0 anchors "no pain" and 10 anchors "pain as bad as you can imagine." The mean daily average NRS pain score was derived from the daily index knee pain ratings recorded by participants in an electronic diary (e-diary) on the last 4 days prior to randomization. A negative change indicates a reduction/improvement from baseline.

    Measured: Baseline and Weeks 1, 2, 3, 4 and EOT (up to 4 weeks)

  12. Change from Baseline Patient Global Assessment (PGA) at Weeks 1, 2, 4 and EOT

    The PGA is an 11-point NRS scale used to capture the participant's overall impression at the time of the assessment in the index knee. This is a single question and the score ranges from 0 to 10, where 0 anchors "very good" and 10 anchors "very poor." A negative change indicates a reduction/improvement from baseline.

    Measured: Baseline and Weeks 1, 2, 4 and EOT (up to 4 weeks)

  13. Percentage of Participants who Achieves ≥ 30% Decrease from Baseline to EOT in WOMAC Pain Subscale Score

    This is the percentage of participants who has a reduction from baseline to EOT in WOMAC pain subscale score of ≥ 30%. WOMAC is a tri-dimensional, self-administered, patient-centered health status questionnaire designed to capture the elements of pain, stiffness and physical function in participants with OA of the knee and/or hip joints. The questionnaire consists of 24 questions, which are divided into three subscales: pain (5 questions), stiffness (2 questions) and physical function (17 questions). Each question is scored using 11-point NRS scale ranging from 0 (none) to 10 (extreme). The pain subscale contains five questions that ask about pain during the last 48 hours caused by arthritis in the index knee.

    Measured: Baseline and EOT (up to 4 weeks)

  14. Percentage of Participants who Achieves ≥ 50% Decrease from Baseline to EOT in WOMAC Pain Subscale Score

    This is the percentage of participants who has a reduction from baseline to EOT in WOMAC pain subscale score of ≥ 50%. WOMAC is a tri-dimensional, self-administered, patient-centered health status questionnaire designed to capture the elements of pain, stiffness and physical function in participants with OA of the knee and/or hip joints. The questionnaire consists of 24 questions, which are divided into three subscales: pain (5 questions), stiffness (2 questions) and physical function (17 questions). Each question is scored using 11-point NRS scale ranging from 0 (none) to 10 (extreme). The pain subscale contains five questions that ask about pain during the last 48 hours caused by arthritis in the index knee.

    Measured: Baseline and EOT (up to 4 weeks)

  15. Number of Participants with Treatment-Emergent Adverse Events

    A TEAE is defined as an adverse event (AE) which starts or worsens after the first dose of study drug until 30 days after taking the last dose of study drug. This includes abnormal laboratory tests, vital signs or electrocardiogram data that are defined as AEs if the abnormality induces clinical signs or symptoms, requires active intervention, interruption or discontinuation of study drug or is clinically significant in the investigator's opinion.

    Measured: From first dose of study drug up to 30 days after last dose of study drug (up to 8 weeks)

  16. Number of Participants with an Affirmative Response in Columbia - Suicide Severity Rating Scale (C-SSRS): Suicidal Ideation

    C-SSRS is a questionnaire used for suicide assessment, where participants respond to these questions: (1) Wish to be dead; (2) Non-specific active suicidal thoughts; (3) Active suicidal ideation with any methods (not plan) without intent to act; (4) Active suicidal ideation with some intent to act, without specific plan; and (5) Active suicidal ideation with specific plan and intent.

    Measured: From first dose of study drug up to end of study (up to 8 weeks)

  17. Number of Participants with an Affirmative Response in CSSRS: Suicidal Behavior

    C-SSRS is a questionnaire used for suicide assessment, where participants respond to these questions: (1) Preparatory acts or behavior; (2) Aborted attempt; (3) Interrupted attempt; (4) Actual attempt; and (5) Completed suicide.

    Measured: From first dose of study drug up to end of study (up to 8 weeks)

  18. Number of Participants with an Affirmative Response in CSSRS: Suicidal Ideation or Behavior

    C-SSRS is a questionnaire used for suicide assessment, where participants respond to any one of the ten suicidal ideation and behavior questions.

    Measured: From first dose of study drug up to end of study (up to 8 weeks)

  19. Number of Participants with an Affirmative Response in CSSRS: Self-injurious Behavior without Suicidal Intent

    C-SSRS is a questionnaire used for suicide assessment, where participants respond to the question "Has subject engaged in Non-Suicidal Self-Injurious Behavior?"

    Measured: From first dose of study drug up to end of study (up to 8 weeks)

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted20 Nov 2015 (estimated)
  2. Study start16 Feb 2016
  3. Primary completion28 Aug 2017
  4. Study completion29 Sep 2017

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
Triple blind
Who is masked
Participant, Investigator, Outcomes assessor
Enrolment
215 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT02611466
Sponsor's protocol ID
7962-CL-0022
Other IDs
2014-004996-22, 2014
Acronym
OAK
Status last verified
Oct 2024
First submitted
19 Nov 2015
Last updated
31 Oct 2024
Results posted
No
Data monitoring committee
Yes
Individual data sharing
Yes: Access to anonymized individual participant level data collected during the study, in addition to study-related supporting documentation, is planned for studies conducted with approved product indications and formulations, as well as products terminated during development. Studies conducted with product indications or formulations that remain active in development are assessed after study completion to determine if Individual Participant Data can be shared. Further details on Astellas' data sharing policy can be found at https://www.clinicaltrials.astellas.com/transparency/.

Publications

  • Watt FE, Blauwet MB, Fakhoury A, Jacobs H, Smulders R, Lane NE. Tropomyosin-related kinase A (TrkA) inhibition for the treatment of painful knee osteoarthritis: results from a randomized controlled phase 2a trial. Osteoarthritis Cartilage. 2019 Nov;27(11):1590-1598. doi: 10.1016/j.joca.2019.05.029. Epub 2019 Jul 26.

    PubMed 31356878

Questions about this trial

What is this clinical trial studying?

A Phase 2 study testing ASP7962 and Naproxen in people with Osteoarthritis of the Knee and Chronic Lower Back Pain, run by Astellas Pharma Europe B.V. at 34 sites in 6 countries.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 23 inclusion and 56 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 31 Oct 2024. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 34 sites in Hungary, Spain, Germany, Czechia, United Kingdom and 1 more country. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Change from Baseline to Week 4 in Western Ontario and McMaster Universities Arthritis Index (WOMAC) Pain Subscale Score (time frame: Baseline and Week 4). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT02611466, which also lists 1 linked publication.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 31 Oct 2024.

AzTrials uses cookies for analytics and advertising. You can accept or reject them; the site works either way. Privacy Policy.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in